Nonobstructive azoospermia (NOA) denotes the absence of sperm in the ejaculate due to impaired spermatogenesis. Approximately 60% of azoospermic men have NOA. The causes include genetic, endocrine, and iatrogenic factors, with conditions like Klinefelter syndrome and hormonal imbalances playing significant roles. Diagnosis involves centrifugation of semen samples with failure to detect sperm in the centrifuged pellet. Sperm can be detected in 35% of men suspected of NOA. Treatment primarily relies on advanced reproductive techniques, with microscopic testicular sperm extraction (micro-TESE) and in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) offering benefits and enabling biological fatherhood for men with NOA. The success rates for sperm retrieval during micro-TESE vary depending on the underlying cause. Collaboration between urologists and reproductive specialists is crucial for optimal management. Prognosis varies by underlying condition, with testicular diseases often irreparable. Males with NOA face increased risks of additional health conditions and malignancies. Genetic research aims to enhance diagnostic capabilities and reduce reliance on ART. Advancements in targeted therapy could alleviate the need for costly and invasive treatments, benefiting both affected males and their partners.